Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from CellSource Co., Ltd. ( (JP:4880) ) is now available.
CellSource Co., Ltd. reported a notable increase in its daily average number of contract processing orders for June 2025, driven by a significant rise in blood-derived orders from its hybrid orthopedics segment. The company continues to strengthen its operations in self-funded orthopedics and hybrid orthopedics, with a focus on maintaining order volumes and expanding partnerships with key medical institutions.
The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology sector, focusing on contract processing services for blood-derived and adipose-derived products, particularly in orthopedics. The company is listed on the Tokyo Stock Exchange and aims to enhance its market presence through strategic partnerships with medical institutions.
Average Trading Volume: 61,786
Technical Sentiment Signal: Sell
Current Market Cap: Yen13.22B
Learn more about 4880 stock on TipRanks’ Stock Analysis page.